Cancer specific-splicing ribozyme and use thereof
The present invention relates to a recombination vector, a transformation cell into which the recombinant vector is introduced, a ribozyme expressed from the recombination vector, a prophylactic or therapeutic composition for liver cancer comprising the recombination vector and the ribozyme, and a therapeutic method for liver cancer using the composition, said recombination vector comprising: a tissue-specific promoter; and a ribozyme-target gene expression cassette comprising a trans-splicing ribozyme targeting a cancer-specific gene and a target gene connected to the 3′ exon of the ribozyme, wherein a splicing donor/splicing acceptor sequence (SD/SA sequence) is connected to the 5′ end of the ribozyme-target gene expression cassette, woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) is connected to the 3′ end of the ribozyme-target gene expression cassette, and a nucleic acid sequence recognizing a micro RNA-122a (microRNA-122a, miR-122a) is further connected to the 3′ end of the WPRE.
1. A recombinant vector comprising:
(i) a phosphoenolpyruvate carboxykinase (PEPCK) promoter as a liver cell-specific promoter comprising a nucleic acid sequence of SEQ ID NO: 2; and
(ii) a ribozyme-target gene expression cassette comprising a telomerase reverse transcriptase (TERT) mRNA as a trans-splicing ribozyme targeting a cancer-specific gene and a herpes simplex virus-thymidine kinase (HSVtk) gene as a target gene linked to the 3′ exon of the ribozyme,
wherein a splicing donor/splicing acceptor sequence (SD/SA sequence) is linked to the 5′ end of the ribozyme-target gene expression cassette and a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) is linked to the 3′ end of the ribozyme-target gene expression cassette, and
wherein (iii) a nucleic acid sequence that binds complementarily to a micro RNA-122a (microRNA-122a, miR-122a) is further linked to the 3′ end of the WPRE.
2. The recombinant vector of claim 1 , wherein the trans-splicing ribozyme comprises a nucleic acid sequence of SEQ ID NO: 5.
3. The recombinant vector of claim 1 , wherein the HSVtk gene comprises a nucleic acid sequence of SEQ ID NO: 6.
4. A transformed cell into which the recombinant vector of claim 1 is introduced.
5. A ribozyme expressed from the recombinant vector of claim 1 .
6. A pharmaceutical composition for preventing or treating hepatocellular carcinoma, comprising the recombinant vector of claim 1 as an active ingredient.
7. A method for treating hepatocellular carcinoma, comprising administering to a subject in need thereof a pharmaceutically effective amount of the recombinant vector of claim 1 .
8. A pharmaceutical composition for preventing or treating hepatocellular carcinoma, comprising the ribozyme of claim 5 as an active ingredient.
9. A method for treating hepatocellular carcinoma, comprising administering to a subject in need thereof a pharmaceutically effective amount of the ribozyme of claim 5 .